Emetic Potential | Chemotherapy Drug |
High Frequency of emesis >90% | Carmustine (>250 mg/m2)1,3 Cisplatin (≥50 mg/m2)1,3,4 Cyclophosphamide (>1500 mg/m2)1,2,3,4 Dacarbazine1,2,3,4 Lomustine (>60 mg/m2)1 Mechlorethamine1,2,3,4 Streptozocin1,2,3,4 |
Moderate Frequency of emesis 30–90% | Aldesleukin (IL-2) (>12–15 million IU/m2)3 Altretamine3 Arsenic Trioxide3 Azacitidine3,4 Bendamustine3,4 Busulfan (IV, oral >4 mg/kg per day)3,✫ Carboplatin1,2,3,4 Carmustine (≤250 mg/m2)1,3 Cisplatin (<50 mg/m2)1,3 Clofarabine3,4 Cyclophosphamide (<1500 mg/m2)1,2,3,4 Cytarabine (>1000 mg/m2)1,2,4 Dactinomycin3 Daunorubicin2,3,4 | Doxorubicin1,2,3,4 Epirubicin2,3,4 Idarubicin1,2,3,4 Interferon alfa (≥10 million IU/m2)3 Ifosfamide1,2,3,4 Irinotecan1,2,3,4 Melphalan (IV)1,3 Methotrexate (>250 mg/m2)1,3 Oxaliplatin2,3,4 Pentostatin✫ Procarbazine1 Romidepsin✫ Temozolomide3,4 |
Low Frequency of emesis 10–30% | Aldesleukin (IL-2) (<12 million IU/m2)3 Bortezomib2,4 Cabazitaxel3 Capecitabine4 Cetuximab2,4 Cytarabine (<1000 mg/m2)1,2,4 Daunorubicin, Liposomal✫ Decitabine✫ Denileukin diftitox✫ Docetaxel1,2,3,4 Doxorubicin, Liposomal3,4 Eribulin3 Etoposide1,2,3,4 Everolimus4 Fluorouracil2,3,4 Gemcitabine1,2,3,4 Imatinib✫ Interferon alfa (>5 to <10 million IU/m2)3 Ixabepilone3,4 | Lapatinib4 Lenalidomide4 Methotrexate (>50 mg/m2 to <250 mg/m2)1,3 Mitomycin1,2,3,4 Mitoxantrone2,3,4 Nelarabine✫ Paclitaxel1,2,3,4 Paclitaxel, albumin-bound suspension3 Panitumumab4 Pazopanib✫ Pemetrexed2,3,4 Pralatrexate3 Sunitinib4 Temsirolimus4 Teniposide1 Thalidomide4 Thiotepa1 Topotecan1,2,3,4 |
Minimal Frequency of emesis <10% | Alemtuzumab3 Asparaginase3 Bevacizumab3,4 Bleomycin1,2,3,4 Busulfan (oral, <4 mg/kg per day)1 Chlorambucil1,4 Cladribine1,2,3,4 Dasatinib✫ Erlotinib4 Fludarabine1,2,3,4 Gefitinib4 Hydroxyurea1,4 Interferon alfa (≤5 million IU/m2)3 Ipilimumab3 | Melphalan (oral)1,4 Mercaptopurine1 Methotrexate (<50 mg/m2)1,3,4 Nilotinib✫ Ofatumumab3 Pegaspargase3 Rituximab2,3,4 Sorafenib4 Thioguanine (oral)1,4 Trastuzumab3 Vinblastine1,2,3,4 Vincristine1,2,3,4 Vinorelbine1,2,3,4 |
|
Classifications are adapted from references 1–4. Each agent is referenced to a specific guideline. When discrepancies existed among guidelines, the author classified the agent on personal opinion and referenced the guideline that supported the classification chosen. If the agent was not classified by a clinical guideline or the clinical guideline classification was in doubt, the classification was based on the incidence of emesis documented in product labeling ✫Classified based on the incidence of emesis documented in product labeling |